CA-OPTIV-SECURITY
6.3.2019 16:07:03 CET | Business Wire | Press release
Most organizations conduct annual risk assessments, identify gaps, and receive recommendations for how to remediate those gaps. But many lack the resources to follow through on planning and operationalization. Based on strategies developed or assessments performed, many organizations know what to do but often not how to do it. Optiv Security , the world’s leading security solutions integrator, today announced its new Risk Transformation ServiceTM , an end-to-end solution that includes strategy execution.
Designed to enable clients around the world to better evaluate current risk against acceptable risk, Optiv’s Risk Transformation ServiceTM helps clients develop strategies that drive cohesive cybersecurity programs, execute on those strategies to mitigate enterprise risk, and achieve measurable outcomes. The service puts business strategy and risk at the heart of cyber decision-making with two distinct options:
- The Enterprise Risk Transformation Service TM helps organizations execute on risk transformation based on business objectives, results of an existing strategy or assessment, and a list of desired improvements or future mode of operation. This service includes program management, quality assurance and oversight over all or parts of a transformation or remediation initiative.
- The Quickstart Risk Transformation Service TM enables mid-sized organizations to get started with a risk-centric model for cybersecurity and aids them in the first steps of execution of their transformation roadmap. Optiv helps these clients set and execute a strategy, engaging with them from start to finish.
“Organizations today are adopting new risk and compliance principles to achieve business resilience,” said Dustin Owens, Optiv’s vice president, risk advisory. “As IT risk management evolves to more holistic operational risk management, it is being integrated into the fabric of organizations. This means that security teams are now a critical component to the overall business risk strategy.”
Owens continued, “As a result, adaptive, risk-based decision-making is becoming core to business agility and resilience, taking over from the antiquated check-the-box, compliance-based approach of the past. It’s high time for companies to embrace the risk revolution. They need to take a stance against the outside-in approach – which is predicated on continuously responding to legislative and regulatory requirements, specific threats, and other outside factors – and rewrite how they manage cybersecurity by proactively addressing all aspects of cybersecurity risk, including privacy and governance , cyber resilience, and risk optimization.”
Optiv’s new Risk Transformation ServiceTM is part of the company’s complete continuum of fully integrated cybersecurity risk services, which are focused on resolving three prevalent business issues:
- The need for risk governance – Optiv helps clients understand where critical assets are located, why they are important, how they are protected and who has access; and as these variables change, how their risk profile changes. This enables organizations to make security decisions based on risk so they can move faster, safely.
- Volume and velocity of change – Optiv allows clients to embrace the fast pace of digital transformation initiatives and deal with constant operational chaos simultaneously by helping them execute adaptive cyber resilience capabilities.
- Articulating security health to the business and board – Optiv provides security teams with everything they need to articulate risk and security performance in business terms by enabling them to effectively measure, monitor and report on security posture and align security to business objectives. This allows security teams to influence better decision-making and improve overall business health.
Please visit Optiv’s website to learn more about risk transformation or the company’s overarching approach to risk management .
Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn:
www.linkedin.com/company/optiv-inc
Facebook:
www.facebook.com/optivinc
YouTube:
www.youtube.com/c/OptivInc
Blog:
www.optiv.com/explore-optiv-insights/blog
About Optiv Security
Optiv helps clients plan, build and run successful cybersecurity programs that achieve business objectives through our depth and breadth of cybersecurity offerings, extensive capabilities and proven expertise in cybersecurity, integration and cyber operational services. Optiv maintains premium partnerships with more than 350 of the leading cybersecurity technology manufacturers. For more information, visit www.optiv.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190306005475/en/
Contact:
Brett Ater (913) 304-7683 Brett.ater@optiv.com or Jason Cook (816) 701-3374 Jason.cook@optiv.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
